Company intelligence / Profile preview

NovalGen

Northwood Hills, Middlesex, United Kingdomnovalgen.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 1

Overview

Lead program NVG-111 is an ROR1 targeting bispecific antibody T cell engager expected to enter clinical development in H1 2021. No active clinical trials were found on ClinicalTrials.gov as of the search results.

Therapeutic areas: Oncology
Modalities: Bispecific antibodiesT cell engagers
Industry: Biotech

Drug pipeline

7 assets

NVG-111

6 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on NovalGen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NovalGen.

Explore the full profile